Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earl ...

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estima ...

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pretreated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in blood is an important parameter of clinical activity for tebentafusp in uveal melanoma and for brenetafusp across different tumor types (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., ...

Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2024 Cantor Global ...

Bevan Goldswain/E+ via Getty Images Immunocore (NASDAQ:IMCR) has made significant progress in being able to use its proprietary ImmTAX platform to develop T-cell receptors [TCRs] against a variety of types of cancer. It has already received FDA approval of Kimmtrak for the treatment of patients with advanced or metastatic uveal melanoma who are HLAA*02:01-positive. Sales for this drug franchise continue to climb, especially when you consider the reported number. It was stated that in Q2 of 2024, sales of Ki ...

a Toshe_O Immunocore Holdings plc (NASDAQ:IMCR) is a commercial-stage biotechnology company that develops immunotherapies for cancer, infectious diseases, and autoimmune conditions. Its leading commercial product, KIMMTRAK, is a bispecific protein for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. KIMMTRAK is currently approved in 38 countries, including the US, EU, Canada, Australia, and the UK, showing a promising revenue trajectory in 2024. Additionally, IMCR has a diverse pi ...

Immunocore Holdings plc (NASDAQ:IMCR) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Mohammed Dar - CMO Michael Yee - ...

Exhibit 99.1 IMMUNOCORE Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing, following conversion of Phase 2/3 trial – expect to complete enrollment in 1H 2026 Registrational Phase 3 (PRISM-MEL-301) evaluating brenetafusp + nivolumab in first-line cutaneous melanoma started randomization Pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | --- | --- | |------------- ...

First registrational Phase 3 trial investigating PRAME-targeted therapy "We are very proud to have started the registrational program for brenetafusp, our PRAME candidate, supported by the recent promising brenetafusp monotherapy data in late-line cutaneous melanoma" said Mohammed Dar, Senior Vice President, Clinical Development, and Chief Medical Officer, Immunocore. "The PRISM-MEL301 trial – the first Phase 3 trial for any PRAME-targeted therapy – will test whether combining brenetafusp with nivolumab may ...